47.05 -0.14 (-0.29%)
After hours: 4:12PM EDT
|Bid||47.22 x 900|
|Ask||47.25 x 900|
|Day's Range||45.88 - 47.27|
|52 Week Range||26.10 - 47.27|
|Beta (3Y Monthly)||1.44|
|PE Ratio (TTM)||40.37|
|Forward Dividend & Yield||0.16 (0.41%)|
|1y Target Est||N/A|
Introduction of multiple products within the Spinal Hardware, balanced revenue growth across key operating segments and robust international sales perk up NuVasive's (NUVA) share price.
This impending divestment remains integral to Haemonetics' (HAE) asset optimization strategy that aims at improving its operational performance and focusing on core competencies.
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
The termination of discussion related to Straumann's iTero distribution is a setback for Align Technologies (ALGN), which is currently focusing on expanding its market base for scanners.
LabCorp's (LH) Diagnostics business sees an organic uptick in terms of both revenues and volumes in spite of further price reductions.
The termination of the Straumann agreement comes as a setback for Align Technologies (ALGN), which is currently focusing on expanding its market base for scanners.
Computer Programs and Systems' (CPSI ) move indicates its efforts to strengthen foothold in the healthcare information technology (HCIT) space.
The latest development in Align Technology's (ALGN) iTero arm is expected to be a perfect strategic fit for the company as it will help it further grow its patient base for intraoral scanner.
Insulet (PODD) gains from steady global expansion as well as rollout of innovative products like Omnipod DASH and Omnipod Horizon automated insulin delivery system.
Boston Scientific (BSX) is pulling out all the stops to strengthen its core businesses as well as invest in new technologies and the overseas markets.
Medtronic's (MDT) data indicates that Guardian Connect will enable patients to better understand glucose trends and increase Time in Range.
Banking on product unveilings and a better sales force performance, Integra LifeSciences (IART) pins hopes on accelerated organic growth in the second half of 2019.
Bruker Corp NASDAQ/NGS:BRKRView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BRKR with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BRKR. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BRKR had net inflows of $1.01 billion over the last one-month. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.